Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

This is a Phase 1, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL952 in adult part…

Late-onset Pompe Disease

Estimated

~$10 – $8,750

Denali Therapeutics Inc.NCT07354724